TerrAscend Competitors

TerrAscend (OTCMKTS:TRSSF) and Abacus Health Products (OTCMKTS:ABAHF) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, earnings, valuation, risk and dividends.

Valuation and Earnings

This table compares TerrAscend and Abacus Health Products' gross revenue, earnings per share and valuation.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for TerrAscend and Abacus Health Products, as provided by MarketBeat.com.

TerrAscend currently has a consensus target price of $18.5417, indicating a potential upside of 86.35%. Given TerrAscend's higher probable upside, research analysts plainly believe TerrAscend is more favorable than Abacus Health Products.

Profitability

This table compares TerrAscend and Abacus Health Products' net margins, return on equity and return on assets.

Summary

TerrAscend beats Abacus Health Products on 2 of the 2 factors compared between the two stocks.

Acreage (OTCMKTS:ACRGF) and TerrAscend (OTCMKTS:TRSSF) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, valuation, dividends and analyst recommendations.

Valuation & Earnings

This table compares Acreage and TerrAscend's top-line revenue, earnings per share and valuation.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Acreage and TerrAscend, as reported by MarketBeat.

Acreage currently has a consensus price target of $8.4333, indicating a potential upside of 204.45%. TerrAscend has a consensus price target of $18.5417, indicating a potential upside of 86.35%. Given Acreage's higher possible upside, equities research analysts plainly believe Acreage is more favorable than TerrAscend.

Profitability

This table compares Acreage and TerrAscend's net margins, return on equity and return on assets.

Summary

TerrAscend beats Acreage on 2 of the 3 factors compared between the two stocks.

Applied Biosciences (OTCMKTS:APPB) and TerrAscend (OTCMKTS:TRSSF) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, profitability, valuation, dividends and institutional ownership.

Analyst Recommendations

This is a breakdown of recent ratings for Applied Biosciences and TerrAscend, as reported by MarketBeat.

TerrAscend has a consensus price target of $18.5417, suggesting a potential upside of 86.35%. Given TerrAscend's higher probable upside, analysts clearly believe TerrAscend is more favorable than Applied Biosciences.

Earnings and Valuation

This table compares Applied Biosciences and TerrAscend's revenue, earnings per share (EPS) and valuation.

Profitability

This table compares Applied Biosciences and TerrAscend's net margins, return on equity and return on assets.

Summary

TerrAscend beats Applied Biosciences on 2 of the 2 factors compared between the two stocks.

Ayr Strategies (OTCMKTS:AYRSF) and TerrAscend (OTCMKTS:TRSSF) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, valuation, profitability and analyst recommendations.

Earnings and Valuation

This table compares Ayr Strategies and TerrAscend's gross revenue, earnings per share and valuation.

Profitability

This table compares Ayr Strategies and TerrAscend's net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of recent recommendations for Ayr Strategies and TerrAscend, as provided by MarketBeat.com.

Ayr Strategies currently has a consensus target price of $34.8571, suggesting a potential upside of 63.96%. TerrAscend has a consensus target price of $18.5417, suggesting a potential upside of 86.35%. Given TerrAscend's stronger consensus rating and higher possible upside, analysts plainly believe TerrAscend is more favorable than Ayr Strategies.

Summary

TerrAscend beats Ayr Strategies on 3 of the 3 factors compared between the two stocks.

TerrAscend (OTCMKTS:TRSSF) and Can B (NASDAQ:CANB) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, earnings, valuation and risk.

Valuation & Earnings

This table compares TerrAscend and Can B's gross revenue, earnings per share and valuation.

Profitability

This table compares TerrAscend and Can B's net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of recent ratings and price targets for TerrAscend and Can B, as provided by MarketBeat.

TerrAscend presently has a consensus price target of $18.5417, indicating a potential upside of 86.35%. Given TerrAscend's higher probable upside, equities analysts clearly believe TerrAscend is more favorable than Can B.

Summary

TerrAscend beats Can B on 2 of the 2 factors compared between the two stocks.

TerrAscend (OTCMKTS:TRSSF) and Cansortium (OTCMKTS:CNTMF) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, earnings, valuation and risk.

Valuation & Earnings

This table compares TerrAscend and Cansortium's gross revenue, earnings per share and valuation.

Profitability

This table compares TerrAscend and Cansortium's net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of recent ratings and price targets for TerrAscend and Cansortium, as provided by MarketBeat.

TerrAscend presently has a consensus price target of $18.5417, indicating a potential upside of 86.35%. Cansortium has a consensus price target of $1.20, indicating a potential upside of 6.10%. Given TerrAscend's higher probable upside, equities analysts clearly believe TerrAscend is more favorable than Cansortium.

Summary

TerrAscend beats Cansortium on 2 of the 2 factors compared between the two stocks.